Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QGEN Stock Forecast 2026-2027
$38.00
Current Price
$7.84B
Market Cap
Buy 9
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to QGEN Price Targets
+55.3%
To High Target of $59.00
+13.2%
To Median Target of $43.00
-5.3%
To Low Target of $36.00
QGEN Price Momentum
-5.2%
1 Week Change
+0.7%
1 Month Change
-20.8%
1 Year Change
-19.7%
Year-to-Date Change
-34.3%
From 52W High of $57.82
+16.8%
From 52W Low of $32.53
📊 TOP ANALYST CALLS
Did QGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if QIAGEN is one of their latest high-conviction picks.
Latest QGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, QGEN has a bullish consensus with a median price target of $43.00 (ranging from $36.00 to $59.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $38.00, the median forecast implies a 13.2% upside. This outlook is supported by 9 Buy, 6 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QGEN Analyst Ratings
9
Buy
6
Hold
0
Sell
QGEN Price Target Range
Low
$36.00
Average
$43.00
High
$59.00
Current: $38.00
Latest QGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 23, 2026 | Morgan Stanley | Overweight | Upgrade | $N/A | |
| May 18, 2026 | Stifel | Hold | Maintains | $N/A | |
| May 7, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Apr 29, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Apr 29, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Apr 29, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Apr 29, 2026 | Baird | Outperform | Upgrade | $N/A | |
| Apr 14, 2026 | Barclays | Equal-Weight | Downgrade | $N/A | |
| Mar 13, 2026 | Deutsche Bank | Buy | Upgrade | $N/A | |
| Feb 6, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Feb 6, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 6, 2026 | Stifel | Hold | Maintains | $N/A | |
| Jan 22, 2026 | Deutsche Bank | Hold | Downgrade | $N/A | |
| Dec 15, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Dec 11, 2025 | Citigroup | Neutral | Downgrade | $N/A | |
| Oct 2, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Aug 7, 2025 | UBS | Neutral | Maintains | $N/A | |
| Jun 26, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Jun 24, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Apr 21, 2025 | Baird | Neutral | Maintains | $N/A |
QIAGEN N.V. (QGEN) Competitors
The following stocks are similar to QIAGEN based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
QIAGEN N.V. (QGEN) Financial Data
QIAGEN N.V. has a market capitalization of $7.84B with a P/E ratio of 20.0x. The company generates $2.10B in trailing twelve-month revenue with a 19.2% profit margin.
Revenue growth is +1.8% quarter-over-quarter, while maintaining an operating margin of +23.8% and return on equity of +11.9%.
Valuation Metrics
Market Cap
$7.84B
Enterprise Value
$9.10B
P/E Ratio
20.0x
PEG Ratio
-0.8x
Price/Sales
3.8x
Growth & Margins
Revenue Growth (YoY)
+1.8%
Gross Margin
+62.9%
Operating Margin
+23.8%
Net Margin
+19.2%
EPS Growth
-25.0%
Financial Health
Cash/Price Ratio
+8.2%
Current Ratio
3.2x
Debt/Equity
50.0x
ROE
+11.9%
ROA
+6.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
QIAGEN N.V. (QGEN) Business Model
About QIAGEN N.V.
What They Do
Provides solutions for molecular insights from samples.
Business Model
QIAGEN generates revenue by offering a wide range of products and services that facilitate the extraction and analysis of DNA, RNA, and proteins. Its business model includes selling over 500 core products, such as disposable kits and automated workstations, to various industries including healthcare, forensics, and academic research.
Additional Information
Founded in 1984, QIAGEN operates in over 130 countries and serves more than 500,000 customers globally. The company has a strong focus on innovation and has a history of strategic acquisitions to enhance its capabilities in diagnostics and bioinformatics. Led by CEO Thierry Bernard, QIAGEN aims to advance scientific discovery and personalized medicine.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
5,500
CEO
Mr. Thierry L. Bernard
Country
Netherlands
IPO Year
1996
Website
www.qiagen.comQIAGEN N.V. (QGEN) Latest News & Analysis
Latest News
Quick Summary
Qiagen N.V. (QGEN) held a shareholder/analyst call, discussing company performance and future outlook. Details from the call can provide insights for investors.
Why It Matters
The Qiagen shareholder/analyst call could reveal insights on financial performance, strategic direction, and future growth prospects, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Qiagen N.V. (QGEN) has announced discussions on its digital PCR technology and its applications in analyzing environmental samples, highlighting advancements in this area.
Why It Matters
Qiagen's focus on digital PCR technology indicates potential growth in environmental testing markets, which could enhance revenue streams and attract investor interest in innovative biotech applications.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
QGEN expands QIAcuity with new gene expression assays, multiplexing, automation, and analysis tools to enhance dPCR adoption.
Why It Matters
QGEN's expansion enhances its product offerings, potentially increasing market share in dPCR. This could lead to higher revenue and improved competitive positioning, impacting investor sentiment positively.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
QIAGEN N.V. has expanded its QIAcuity digital PCR ecosystem to enhance gene expression capabilities and workflow standardization, aiming to support growing adoption in life sciences and biopharma sectors.
Why It Matters
QIAGEN's expansion of its dPCR ecosystem signals growth potential in life sciences and biopharma, likely boosting revenue and market share, which is favorable for stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Qiagen (QGEN) reported earnings 30 days ago; investors should monitor upcoming developments for potential stock movements.
Why It Matters
Qiagen's recent earnings report may influence investor sentiment and stock performance. Future guidance or market reactions will impact stock valuation and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
1 month ago
Quick Summary
Pomerantz LLP is investigating claims for investors of Qiagen N.V. (NYSE: QGEN) as of June 4, 2026.
Why It Matters
Investigation into Qiagen could signal potential legal issues or financial irregularities, impacting stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About QGEN Stock
What is QIAGEN N.V.'s (QGEN) stock forecast for 2027?
Based on our analysis of 17 Wall Street analysts, QIAGEN N.V. (QGEN) has a median price target of $43.00. The highest price target is $59.00 and the lowest is $36.00.
Is QGEN stock a good investment in 2027?
According to current analyst ratings, QGEN has 9 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $38.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QGEN stock?
Wall Street analysts predict QGEN stock could reach $43.00 in the next 12 months. This represents a 13.2% increase from the current price of $38.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is QIAGEN N.V.'s business model?
QIAGEN generates revenue by offering a wide range of products and services that facilitate the extraction and analysis of DNA, RNA, and proteins. Its business model includes selling over 500 core products, such as disposable kits and automated workstations, to various industries including healthcare, forensics, and academic research.
What is the highest forecasted price for QGEN QIAGEN N.V.?
The highest price target for QGEN is $59.00 from at , which represents a 55.3% increase from the current price of $38.00.
What is the lowest forecasted price for QGEN QIAGEN N.V.?
Price targets from Wall Street analysts for QGEN are not currently available. The stock is trading at $38.00.
What is the overall QGEN consensus from analysts for QIAGEN N.V.?
The overall analyst consensus for QGEN is bullish. Out of 17 Wall Street analysts, 9 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $43.00.
How accurate are QGEN stock price projections?
Stock price projections, including those for QIAGEN N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 10:46 AM UTC